Sadly, there has been very little research on minority populations with chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr. Slager in partnership with Dr. Esteban Braggio, Mayo Clinic, is hoping to start to remedy that knowledge gap with a trial specifically for minorities with CLL.
As new and better treatments are developed to treat Chronic Lymphocytic Leukemia, and Small Lymphocytic Lymphoma (CLL / SLL), testing for subtypes of the disease is becoming more important for prognosis and selection of the best treatment options.
CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL / SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You
At the virtual American Society of Hematology Annual Meeting and Exposition or ASH 2020, Dr. Alexey Danilov of City of Hope was interviewed by CLL Society’s Steve Bloom on his important preclinical research to address one of the significant unmet needs in CLL / SLL/ patients: resistant to venetoclax and/or ibrutinib.
The CAPTIVATE study data has been highly anticipated. At ASH 2020, we got important results. Dr. Wierda presented the results of Minimal (Measurable) Residual Disease (MRD) cohort using MRD status to guide therapy: Undetectable MRD (uMRD) was achieved in >2/3 of patients with 12 cycles of I+V, and the 30 months progression free survival or PFS rates was an impressive ≥95%.
This was accepted as a late breaking abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021), reflecting its importance to the best management of relapsed/ refractory (R/R) chronic lymphocytic leukemia (CLL). Investigators from multiple CLL centers in Europe, Australia, and North America were involved in this research.
Understanding Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL / SLL) In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational
ASH 2020: Dr. Tanya Siddiqi provides an Update on the TRANSCEND CLL 004 Trial: Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)
Idelalisib (Zydelig) was once known as CAL-101 and was the most exciting new oral therapy in the CLL world, the shining morning star in the dawn of a new era of treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL).
